Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
02 August 2023 - 2:35PM
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the
“Company”), an agricultural bioscience company, today announced
positive results in the first field test of stacked herbicide
tolerance (“HT”) traits in Camelina. These proprietary stacked HT
Camelina varieties developed by Yield10 demonstrate tolerance to
the application of an over-the-top herbicide for weed control as
well as tolerance to Group 2 herbicide soil residues. These results
represent a key advancement for supporting grower adoption of
stacked HT Camelina for the biofuel feedstock market by enabling
weed control and increased access to acreage previously treated
with Group 2 herbicides. Yield10 is executing a program to develop
and commercialize spring and winter Camelina varieties with stacked
herbicide traits to achieve large acreage adoption of the crop in
North America.
In the second quarter of 2023, Yield10 researchers initiated the
first field tests of candidate E3902 spring Camelina lines deployed
with stacked HT traits intended to provide the plants with
tolerance to the application of an over-the-top broadleaf herbicide
for weed control as well as tolerance to soil residues of Group 2
herbicides, specifically including tolerance to both imidazolinones
(“IMI”) and sulfonylureas (“SU”). Preliminary results of these
field tests indicate that these Camelina lines demonstrate
tolerance to both target herbicide chemistries. By comparison,
significant injury was observed to control E3902 Camelina plants
following application of an over-the-top herbicide and exposure to
increasing concentrations of IMI or SU soil residues. Group 2
herbicides are commonly used to manage weeds in cereal and other
crop rotations and can persist in the soil for months following
use. Yield10 intends to harvest the plants and collect seed yield
and oil yield data in the weeks ahead with the goal of selecting
lead and back-up stacked HT spring E3902 Camelina lines for
commercial development and seed scale-up.
In addition to its program for spring Camelina, Yield10
researchers have also developed candidate stacked HT traits in a
winter Camelina variety, and the first field tests of these stacked
HT Camelina lines are planned for the fall of 2023. In the second
quarter of 2023, Yield10 filed a request for Regulatory Status
Review (RSR) with USDA-APHIS Biotechnology Regulatory Services
(BRS) for stacked herbicide tolerant Camelina under the SECURE
Rule, and a response from the agency is pending.
“The positive field test results with our stacked HT spring
Camelina underscore the significant progress we are making in the
development of elite herbicide tolerant Camelina varieties,” said
Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
“Based on these positive field trial results, we remain firmly
on-track executing our program to develop and commercialize stacked
herbicide tolerant spring and winter Camelina varieties. The
combination of over-the-top broad leaf weed control and tolerance
to Group 2 soil residues is intended to provide significant
differentiation of our elite Camelina varieties from common types
and enable growers to plant Yield10 elite Camelina with confidence
on a large-scale.”
“Yield10’s commercial vision for our Camelina feedstock oil
program is well aligned with the climate impact and sustainability
needs of the biofuel market,” said Oliver Peoples, Ph.D., President
and Chief Executive Officer of Yield10 Bioscience. “Our proprietary
HT Camelina varieties and stacked HT varieties are designed to be
an excellent fit for growers in cover cropping as well as a
seamless fit into crop rotations with other major crops in the U.S.
and Canada. Based on the positive field test results we have
reported over the last year, we remain on track with our plan to
launch our first commercial HT Camelina varieties in 2025 and
following soon thereafter with stacked HT Camelina varieties.”
About the SECURE Rule
The SECURE Rule was published on May 18, 2020 and represents the
first comprehensive revision of APHIS’ biotechnology regulations
since 1987. The revisions enable APHIS to regulate organisms
developed using genetic engineering for plant pest risk with
greater precision and reduce the regulatory burden for developers
of organisms that are unlikely to pose plant pest risks. Once a
specific plant developed through genetic engineering is found not
to require regulation, new varieties of the plant containing the
same genetic modification would similarly not be regulated.
Herbicides must be labeled for use on Camelina plants containing
herbicide tolerance traits under Environmental Protection Agency
regulations.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
that is using its differentiated trait gene discovery platform, the
“Trait Factory”, to develop improved Camelina varieties for the
production of proprietary seed products, and to discover high value
genetic traits for the agriculture and food industries. Our goals
are to efficiently establish a high value seed products business
based on developing superior varieties of Camelina for the
production of feedstock oils, PHA bioplastics and omega-3 (EPA,
DHA+EPA) oils, and to license our yield traits to major seed
companies for commercialization in major row crops, including corn,
soybean and canola. Yield10 is headquartered in Woburn, MA and has
a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon,
Canada.
For more information about the Company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, expectations related to research and development
activities, the expected regulatory path for its traits, the
reproducibility of data from greenhouse and field tests, the start
and timing of completion of field tests and seed scale-up
activities, commercial launch plans and timing, and the overall
progress of Yield10 Bioscience, Inc., constitute forward-looking
statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including the risks and
uncertainties detailed in Yield10 Bioscience's filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024